Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 6,514 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Oral Cavity Clear all
Completed Phase 2 Interventional Results available

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

NCT01685138
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
LDK378
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
4
States / cities
Boston, Massachusetts • St Louis, Missouri • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 21, 2026, 9:17 AM EDT
Completed Phase 3 Interventional

Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women

NCT00326248
View directory record Official record
Conditions
Nausea and Vomiting, Postoperative
Interventions
GW679769 (casopitant)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
26
States / cities
Montgomery, Alabama • Sheffield, Alabama • Phoenix, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 21, 2026, 9:17 AM EDT
Completed Phase 2 Interventional

Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT00072709
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
TCH346
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
21 Years to 80 Years
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 24, 2011 · Synced Oct 21, 2026, 9:17 AM EDT
Recruiting Phase 2 Interventional

Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

NCT04879121
View directory record Official record
Conditions
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Larotrectinib Sulfate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 21, 2026, 9:17 AM EDT
Completed Phase 3 Interventional

S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer

NCT00016406
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, cyclophosphamide, doxorubicin, paclitaxel, surgery
Biological · Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
314
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 204 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 21, 2026, 9:17 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Cancer Associated Thrombosis and Isoquercetin (CATIQ)

NCT02195232
View directory record Official record
Conditions
Thromboembolism of Vein VTE in Colorectal Cancer, Thromboembolism of Vein in Pancreatic Cancer, Thromboembolism of Vein in Non-small Cell Lung Cancer
Interventions
Isoquercetin
Drug
Lead sponsor
Jeffrey Zwicker, MD
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Los Angeles, California • Sacramento, California • West Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 21, 2026, 9:17 AM EDT
Suspended Phase 2 Interventional

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis

NCT04166552
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
Patients will be randomized to receive EHP-101 or Placebo
Drug
Lead sponsor
Emerald Health Pharmaceuticals
Industry
Eligibility
18 Years to 74 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
Phoenix, Arizona • Huntington Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 21, 2026, 9:17 AM EDT
Completed Phase 1 Interventional

Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer

NCT01545947
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
Interventions
CC-223, erlotinib, CC-223, oral azacitidine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 21, 2026, 9:17 AM EDT
Completed Phase 2 Interventional Results available

Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies

NCT04001517
View directory record Official record
Conditions
Dementia With Lewy Bodies (DLB)
Interventions
Neflamapimod
Drug
Lead sponsor
EIP Pharma Inc
Industry
Eligibility
55 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
22
States / cities
La Jolla, California • Santa Monica, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 21, 2026, 9:17 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effect of an Oral Probiotic Tablet on Oral Bacteria and Clinical Measurements (ProBiora3)

NCT01520974
View directory record Official record
Conditions
Oral Health
Interventions
ProBiora3 mints, Placebo tablet
Other
Lead sponsor
Oragenics, Inc.
Industry
Eligibility
18 Years to 35 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 2, 2012 · Synced Oct 21, 2026, 9:17 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety of AT2220 (Duvoglustat) in Pompe Disease

NCT00688597
View directory record Official record
Conditions
Pompe Disease
Interventions
Duvoglustat
Drug
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
18 Years to 74 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 21, 2026, 9:17 AM EDT
Completed Phase 2 Interventional Results available

Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis

NCT03425396
View directory record Official record
Conditions
Uncomplicated Urinary Tract Infection, Cystitis
Interventions
Omadacycline tablets, Nitrofurantoin capsules
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
23
States / cities
Chula Vista, California • La Mesa, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 21, 2026, 9:17 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19

NCT04540185
View directory record Official record
Conditions
Covid19, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection, SARS-CoV-2
Interventions
Biological: oral polio vaccine, Comparable Placebo, NA-831, Comparable Placebo of drug, Combination of oral polio vaccine and NA-831, Comparable Placebo of Oral Polio Vaccine and Placebo of drug
Biological · Drug · Combination Product
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
8
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 21, 2026, 9:17 AM EDT
Completed Phase 1 Interventional

Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B

NCT04629976
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
NCO-48 Fumarate 4 mg, NCO-48 Fumarate 20 mg, Tenofovir Alafenamide 25 mg
Drug
Lead sponsor
Nucorion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Monterey Park, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 21, 2026, 9:17 AM EDT
Completed Phase 3 Interventional

Oral Cleft Prevention Program

NCT00397917
View directory record Official record
Conditions
Cleft Lip, Cleft Palate
Interventions
Folic acid: 4 mg versus 0.4 mg per day
Drug
Lead sponsor
University of Iowa
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 21, 2026, 9:17 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Preliminary Efficacy of Lipoxin Analog BLXA4-ME Oral Rinse for the Treatment of Gingivitis

NCT02342691
View directory record Official record
Conditions
Gingival Inflammation
Interventions
BLXA4, Placebo oral rinse
Drug
Lead sponsor
The Forsyth Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 21, 2026, 9:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Dentinal Hypersensitivity

NCT02542943
View directory record Official record
Conditions
Dentin Sensitivity
Interventions
Experimental Oral Rinse 1, Experimental Oral Rinse 2, Placebo Oral Rinse, Standard fluoride toothpaste
Device · Other · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 21, 2026, 9:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase1, STP7 Cocaine Drug-Drug Interaction Study

NCT06273540
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
STP7 (mavoglurant), Placebo, Cocaine Hydrochloride
Drug
Lead sponsor
Stalicla SA
Industry
Eligibility
18 Years to 59 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 21, 2026, 9:17 AM EDT
Completed Phase 2 Interventional

Study In People With Type 2 Diabetes

NCT00196989
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Pioglitazone, GW677954
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
69
States / cities
Birmingham, Alabama • Northport, Alabama • Chandler, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 21, 2026, 9:17 AM EDT
Completed No phase listed Observational

Quality of Life and Development of Measures in Patients With Cancer of the Oral Cavity

NCT00582413
View directory record Official record
Conditions
Cancer of the Oral Cavity
Interventions
questionnaires
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Oct 21, 2026, 9:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects

NCT00316459
View directory record Official record
Conditions
Healthy, Long QT Syndrome
Interventions
ERB-041
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2007 · Synced Oct 21, 2026, 9:17 AM EDT
Completed Phase 2 Interventional

Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia

NCT00101335
View directory record Official record
Conditions
Head and Neck Cancer, Precancerous Condition
Interventions
celecoxib
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 21, 2026, 9:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects

NCT02411435
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
CAB, RIF
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Oct 21, 2026, 9:17 AM EDT
Recruiting Phase 3 Interventional

A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

NCT07592689
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, DT120
Other · Drug
Lead sponsor
Definium Therapeutics US, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
30
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 21, 2026, 9:17 AM EDT